Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Retinoblastoma 1Retinal Neoplasms 1Oropharyngeal Neoplasms 1Nonsquamous Non-small Cell Lung Cancer 1Melanoma 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 30Nivolumab 30cabozantinib 20Ipilimumab 15Magnetic Resonance Spectroscopy 14belzutifan 13lenvatinib 11Axitinib 9Specimen Handling 8Sunitinib 7durvalumab 5CTLA-4 Antigen 5tislelizumab 4atezolizumab 4Radiosurgery 4Interleukin-2 4Everolimus 4Biopsy 4Bevacizumab 4pazopanib 3avelumab 3aldesleukin 3Immunoglobulin G 3Disulfides 3palbociclib 2fludarabine 2entinostat 2adavosertib 2Surveys and Questionnaires 2Paclitaxel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Carcinoma, Renal Cell × Platinum Compounds × Clear all
NCT05614102 2026-03-31

A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors

Bayer

Phase 1 Active not recruiting
284 enrolled
DermatologicGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡